诱导多能干细胞促进癌症疫苗的开发和评估。
Induced Pluripotent Stem Cells Facilitate the Development and Evaluation of Cancer Vaccines.
发表日期：2024 Aug 06
作者：
Yuewen Zhai, Xinyu Xu, Ji Fang, Fang He, Siwen Li
来源：
CANCER RESEARCH
摘要：
癌症疫苗是一种引发增强抗原特异性免疫反应的方法。诱导多能干细胞（iPSC）由于其固有的抗原表位，具有开发通用疫苗的潜在用途。同时，iPSC 可以进行多能分化，因此是用于生产基于免疫细胞的疫苗的抗原呈递细胞和用于促进肿瘤疫苗的探索和适应性评估的肿瘤类器官的稳定来源。这篇综述描述了 iPSC 对疫苗开发的具体贡献，总结了其不同的发展轨迹，并讨论了其应用的障碍以及潜在的解决方案。
Cancer vaccines are an approach to elicit amplified antigen-specific immune responses. Induced pluripotent stem cells (iPSCs) have potential utility for the development of universal vaccines due to their intrinsic antigenic epitopes. Concurrently, iPSCs can undergo pluripotent differentiation and are thus a stable source of both antigen-presenting cells for producing immune cell-based vaccines and tumor organoids for facilitating the exploration and adaptive assessment of tumor vaccines. This review describes the specific contributions of iPSCs to vaccine development, summarizes their diverse developmental trajectories, and discusses the obstacles to their application along with potential solutions.